Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 7/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | FPR1 | P21462 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | USP7 | Q93009 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3707111 | 0.89 | SMN1; SMN2 (0.55) | SMN1; SMN2LMNACYP2C9POLBCYP3A4 | |
| SCHEMBL3702953 | 0.84 | ALDH1A1 (0.64) | SMN1; SMN2LMNACYP2C9POLBCYP2C19 | |
| SCHEMBL3711099 | 0.83 | USP7 (0.60) | SMN1; SMN2ALDH1A1HTTALOX15USP2 | |
| SCHEMBL3715636 | 0.77 | ALDH1A1 (0.61) | SMN1; SMN2LMNAALDH1A1ALOX15USP2 | |
| SCHEMBL3707512 | 0.75 | ALOX15 (0.70) | SMN1; SMN2LMNACYP2C9POLBCYP2C19 | |
| SCHEMBL3709177 | 0.71 | USP7 (0.57) | SMN1; SMN2ALDH1A1HTTALOX15USP2 | |
| SCHEMBL6721712 | 0.69 | ALOX15 (0.74) | SMN1; SMN2LMNACYP2C9POLBCYP3A4 | |
| SCHEMBL3706307 | 0.69 | USP7 (0.69) | SMN1; SMN2LMNACYP2C9POLBCYP3A4 | |
| SCHEMBL16904825 | 0.69 | ALOX15 (0.63) | SMN1; SMN2LMNACYP2C9POLBCYP3A4 | |
| SCHEMBL3708643 | 0.69 | MEN1 (0.61) | SMN1; SMN2LMNACYP2C9POLBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2208725-A1 | Novel specific inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications | Hybrigenics S.A. (FR) | 2010-07-21 | — | — | EP | claimed |
| US-20220125760-A1 | USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) | UNIVERSITÉ PAUL SABATIER TOULOUSE III (FR) | 2022-04-28 | — | — | US | disclosed |
| EP-3923987-A1 | USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2021-12-22 | — | — | EP | disclosed |
| WO-2020165315-A1 | USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2020-08-20 | — | — | WO | disclosed |
| WO-2010081783-A1 | NOVEL SPECIFIC INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS | HYBRIGENICS SA (FR) | 2010-07-22 | — | — | WO | disclosed |
| WO-2010081783-A1 | NOVEL SPECIFIC INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS | HYBRIGENICS SA (FR) | 2010-07-22 | — | — | WO | disclosed |
| EP-2208725-A1 | Novel specific inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications | Hybrigenics S.A. (FR) | 2010-07-21 | — | — | EP | disclosed |
| EP-2208725-A1 | Novel specific inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications | Hybrigenics S.A. (FR) | 2010-07-21 | — | — | EP | disclosed |